Purpose of review SH2 domain-containing tyrosine phosphatase 2 (SHP2), encoded by PTPN11 plays an important role in regulating signaling from cell surface receptor tyrosine kinases during normal development as well as oncogenesis. Herein we review recently discovered roles of SHP2 in normal and aberrant hematopoiesis along with novel strategies to target it.
INTRODUCTION
SH2 domain-containing tyrosine phosphatase 2 (SHP2), a nonreceptor tyrosine phosphatase is encoded by PTPN11 gene. It is a positive regulator of signaling downstream of several receptor tyrosine kinases such as stem cell growth factor receptor and Fms like tyrosine kinase (FLT3) [1,2 & ]. Recruitment of SHP2 to an activated receptor releases the selfinhibitory conformation and leads to catalytic activation of its phosphatase domain. In addition to its function as a phosphatase, SHP2 also serves as a docking protein to recruit other signaling intermediates through the two amino terminus SH2 domains. Since SHP2 is a positive regulator of cellular signaling leading to proliferation, differentiation, and survival, its constitutive activation is associated with oncogenesis.
SHP2 in hematopoiesis
Normal hematopoietic development and homeostasis is maintained by cell-to-cell interactions between cells of the hematopoietic system and their surroundings as well as through soluble mediators that include growth factors, cytokines, and chemokines. Collectively, these factors constitute a complex niche in which hematopoietic stem cells (HSCs) reside and wherein their function is governed by both cell autonomous genetic programs and niche properties [3] . Given that SHP2 plays a role in signaling through multiple tyrosine kinases in response to different cytokines, deregulation of SHP2 has broad consequences on hematopoiesis [4, 5] . Mouse models with conditional deletion of Ptpn11, the gene encoding SHP2 have conclusively established an indispensable role for SHP2 in regulating normal HSC function [6, 7] . According to general consensus, SHP2 is a positive regulator of hematopoiesis and loss of SHP2 or decrease in its catalytic activity is associated with reduced stem and progenitor cell numbers and function. Reciprocal transplantation experiments have shown that the defects in HSC function because of loss of SHP2 are primarily cell autonomous with no significant involvement of the bone marrow microenvironment [6, 7] . Likewise, in human CD34
þ cord blood cells, knockdown of SHP2 has been associated with decrease in cell growth and colony formation [8] . A similar reduction in colony formation was observed upon expression of SHP2 with a point mutation, resulting in loss of phosphatase function in human CD34
þ cord blood cells [9] . Conversely, a gain of phosphatase function mutant of SHP2 promoted colony formation in this study. Interestingly, expression of a phosphatase domain truncated version of SHP2 with adaptor function intact functioned in a dominant negative manner [9] . These mouse models and human cord blood studies indicate that phosphatase function of SHP2 is integral to normal HSC function.
At the molecular level, modulation in the expression of transcription factors such as GATA2, C/EBPa and induction of p53 independent apoptosis in the stem and progenitor cell compartment have been implicated in deregulation of HSC number and function in response to loss of SHP2 [6, 7] . Thus far, downregulation of the Ras-extracellular regulated kinase (ERK) signaling axis in the absence of SHP2 is considered as the major mediator of the above described molecular changes. Recently RUNX1, a master regulator of hematopoiesis, has been identified as a direct target of SHP2 phosphatase activity [10] . In the progenitor cells, RUNX1 is phosphorylated by Src family kinases and removal of this phosphorylation by SHP2 is required during megakaryocyte differentiation [10] . The dephosphorylation of RUNX1 enabled its association with the transcription factors such as GATA binding factor 1 and SWItch/Sucrose Non-Fermentable chromatin remodeling complex for execution of megakaryocyte terminal differentiation program (Fig. 1) [10] . Consistent with these findings, conditional deletion of Ptpn11 in megakaryocyte lineage cells is associated with suppression of thrombopoietin and integrin signaling, reduction in proplatelets, and development of macrothrombocytopenia [11] . In addition to the megakaryocyte lineage, dephosphorylation of RUNX1 is also required for differentiation of T cells into CD8 þ single positive cells [10] . Thymocytes with deletion of Ptpn11 show increase in RUNX1 phosphorylation and defects in the development of CD8 þ cells [10] . Thus SHP2 plays an important role in regulating the transcriptional activity of RUNX1 during cellular differentiation through its phosphatase activity. Level of RUNX1 activity then determines the differentiation of the progenitor cells along either megakaryocyte or erythroid lineage. While RUNX1 promotes development of megakaryocytes, inhibits erythroid development through repression of Kruppel Like Factor 1 [12] .
In line with this, expression of oncogenic Ptpn11 that is constitutively active blocks erythrocyte differentiation and maturation suggesting that downregulation of SHP2 activity is required for erythrocyte differentiation [13] . Interestingly, a similar block in erythrocyte differentiation was
KEY POINTS
PTPN11 mutations are frequently present in hematological malignancies and carry prognostic significance.
Constitutive activation of SHP2 has both cell autonomous and noncell autonomous role in pathogenesis of myeloid hyperproliferation.
Highly selective small molecule allosteric SHP2 inhibitor, SHP099 is effective in suppressing growth of receptor tyrosine kinase driven tumor cells both in vitro and in vivo. observed as a result of loss of SHP2 activity in the context of phosphatase and tensin homolog (PTEN) deficiency [14 & ]. Contrasting results have been reported on the role of mitogen activated protein kinase\ERK activation in erythropoiesis due to loss or gain of function of SHP2. In one study, MEK inhibitor U0126 inhibited the hyperproliferation of erythroblasts [13] while the other study using trametinib, another MEK inhibitor, phenocopied the loss of SHP2 mediated defect in erythropoiesis [14 & ]. It is possible that these differences are because of off-target effects of the different MEK inhibitors used in the two studies. Further studies are needed to clarify these contradictory observations and further clarify the role SHP2/ERK axis in erythropoiesis. These cell lineage specific functions of SHP2 are going to be valuable while designing strategies to target SHP2 in hematological malignancies.
SHP2 in leukemogenesis
SHP2 is the first phosphatase to be recognized as a bonafide oncogene. Constitutive activation of SHP2 in the hematopoietic stem and progenitor compartment due to point mutations in its N-terminus SH2 domain results in the development of cell autonomous leukemia in different cell lineages independent of the stage of differentiation [15] . In addition to the hematopoietic compartment, PTPN11 has been recognized as an oncogene in 41 different cancer types with Q510, A72, E76, and G503 identified as hotspots of mutation in a panel of 119 tumors [16] . Interestingly, all these mutations have a positive impact on the phosphatase activity of SHP2 through either reducing regulatory N-SH2 domain (A72, E76) interaction with the catalytic domain or alter the active site (G503, Q510) [17, 18] . Mutations in PTPN11 that lead to alterations in the catalytic activity of SHP2 have been implicated in pathogenesis of Noonan syndrome, Leopard syndrome, and juvenile myelomonocytic leukemia (JMML) [4, 5] . PTPN11 is also frequently mutated in secondary acute myeloid leukemia (AML) [19] , relapsed pediatric AML [20] and acute lymphoblastic leukemia [21] . The frequency of PTPN11 mutations in AML is higher in patients older than 60 years [22] and also has prognostic significance. Secondary AML patients carrying mutations in PTPN11 show rapid disease progression and reduced overall survival [19] . In AML, PTPN11 G503A mutation has been reported to co-occur with mixed lineage leukemia (MLL) translocation, MLL-AF10. In a mouse model, coexpression of MLL-AF10 and PTPN11 G503A resulted in accelerated disease development as compared to MLL-AF10 alone [23 && ]. Increase in leukemia stem cell frequency along with rapid AML development is also seen when Ptpn11 E76K is coexpressed with MLL-AF9 fusion oncogene [24] . In presence of mutant PTPN11, the leukemic cells show increase in the transcription of colony stimulating factor 1 (Csf1) and secretion of macrophage colony stimulating factor (M-CSF) resulting in enhanced differentiation of HSCs into myeloid lineage cells [23 && ]. Although coexpression of MLL-AF9 with constitutively active SHP2 does not alter the expression of Meis1 or HoxA9 [24] , it can reverse cytokine induced tyrosine phosphorylation of HoxA9 and HoxA10 leading to sustained expression of CDX4, a homeodomain transcription factor (Fig. 2) [25] . 24] . These studies provide insights into how coexistence of PTPN11 mutations can alter disease progression and drug resistance.
Recent studies have shed novel light on our understanding of the noncell autonomous role of constitutively active SHP2 in leukemogenesis. Bone marrow transplant recipients are known to develop donor cell-derived secondary leukemia. One of the contributing factor resulting in this observation likely relates to the oncogenic signaling initiated by the microenvironment [3, 26] . The microenvironment-induced leukemogenic effects could be a result of the presence of genetic aberrations in the microenvironmental cells or modulation of the niche by leukemic cells [3, 26] . Dong et al. [27 && ] have shown that expression of Noonan syndrome associated leukemogenic Ptpn11 mutations in mesenchymal stem and osteoprogenitor cells can modulate chemokine and cytokine secretion resulting in a favorable environment for recruitment of monocytes to the HSC niche (Fig. 3) cellular transformation. These studies underline the importance of targeting the alterations in the microenvironment for successful therapy of diseases involving germline PTPN11 mutations.
Targeting SHP2 in hematological malignancy
Targeting the aberrant signaling through tyrosine kinase inhibitors (TKI) led to initial success but subsequent acquisition of resistance to TKI because of additional mutations has been a major challenge in the long-term management of these malignancies [28, 29] . Therefore, efforts have shifted to target further downstream mediators of the oncogenic signals [29] . While constitutively active SHP2 leads to the development of hematological malignancies such as JMML, wild-type SHP2 is required by oncogenic tyrosine kinases for cellular transformation [30] [31] [32] . Thus, SHP2 has emerged as a therapeutic target not only for diseases involving PTPN11 mutations but also in malignancies driven by receptor tyrosine kinases such as AML, MPN. However, traditionally phosphatases have been considered as undruggable in part due to the inability to efficiently and selectively target their catalytic site with cell permeable small molecule inhibitors [33] . Protein phosphatases have highly conserved residues around catalytic sites, and therefore attaining selectivity has been a formidable challenge. Over the course of last several years, efforts have been made to develop inhibitors of SHP2 for clinical use based on their activity in vitro and in vivo [34] . However, despite promising preclinical results, little progress has been made in translating these findings into clinic. Thus far, only one SHP2 inhibitor, Sodium Stibogluconate (SB), also known as Pentostam has entered clinical trials. It is one of the first known compounds to irreversibly inhibit SHP2 along with related phosphatases such as SHP1 and PTP1B in hematopoietic cells [35] . Phase I/II clinical trials were conducted with coadministration of SB with IFN-a2B in advanced cancers and melanoma with or without chemotherapy (NCT00629200 and NCT00498979). Though the drug combination was well tolerated in patients with decrease in target phosphoproteins in peripheral blood, no objective disease regression was observed in any of the patients [36] . Development of allosteric inhibitors has been a major step in overcoming nonspecificity in targeting phosphatases. Since allosteric inhibitors do not bind to the catalytic site, they can be targeted to the nonconserved domains of the protein to alter the active site structure and function. The pharmaceutical company, Novartis has recently been successful in identifying a small molecule allosteric inhibitor of SHP2 from a library of compounds [37,38 && ]. SHP099, obtained after a series of optimization steps, is a potent, orally bioavailable allosteric inhibitor of SHP2 that selectively inhibits the proliferation of receptor tyrosine kinase driven cancer cell lines in vitro without impacting BRAF or KRAS driven cancer cells [38 && ]. SHP099 was also shown to be effective in vivo models of tumor xenograft including in AML model. Inhibition of growth of cancer cells correlated with the ability of SHP099 to downregulate ERK signaling pathway with no significant impact on the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway. Interestingly, SHP099 was as effective as the Food and Drug Administration approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, Erlotinib in inhibiting activation of ERK and tumor growth in xenograft models [38 && ]. Additionally, negligible activity against a broad panel of phosphatases, kinases and other potential off target effectors strongly suggest that SHP099 is highly specific for SHP2 [38 && ]. However, it still remains to be seen whether allosteric inhibition will be as successful against leukemogenic SHP2 wherein the self-inhibitory state is perturbed. In addition to the chemically synthesized inhibitors, recently Fumosorinone (Fumos) has been isolated from entomogenous fungi and characterized as an effective inhibitor of SHP2 [39] . Similar to SHP099, Fumos showed significant inhibition of the RAS/ERK pathway downstream of EGFR but was ineffective in the presence of oncogenic RAS or phorbol myristate acetate [39] . With the development and availability of such specific and potent inhibitors of SHP2, the likelihood of moving these drugs in clinic seems imminent.
Some unintended consequences in nonmyeloid lineage cells due to targeting SHP2 for myeloid malignancies have also been described. Zhu and colleagues [14 & ] have shown that inhibition of SHP2 using either a genetic or a chemical approach though successful in ameliorating myeloid cell hyperproliferation induced by loss of PTEN, appeared to have a negative impact on red blood cells, resulting in anemia and shortened overall life span. In these studies, a similar effect was observed when mice were treated with MEK inhibitor, trametinib highlighting the differential role of the MEK/ ERK pathway in myeloid versus erythroid lineages. While proliferation was suppressed in myeloid lineage cells; in the erythroid progenitor cells differentiation into mature red blood cells was blocked [14 & ]. Interestingly, treatment with antioxidants partially rescued these mice from development of anemia by extending the lifespan of erythrocytes but had no significant impact on differentiation Role of SHP2 in hematopoiesis and leukemogenesis Pandey et al.
of erythroblasts [14 & ]. Though the molecular mechanisms for the differential impact of inhibition of Shp2/MEK/ERK on myeloid versus erythroid lineage cells are not clear, AKT hyperphosphorylation may be one of the factors. AKT phosphorylation is abrogated in myeloid cells due to loss of SHP2 in the context of PTEN deficiency; however, it remained elevated in TER119 þ erythroblasts [14 & ]. Therefore, it may be essential to investigate the impact of SHP2 inhibition in cells that are not intended to be targeted especially in the context of additional genetic aberrations present. These deleterious effects on erythroid lineage were not observed by loss of SHP2 alone but only in the presence of concurrent loss of PTEN and SHP2. To this end, PI3K/AKT inhibitors are being actively pursued in preclinical and clinical trials in various hematological malignancies [40] . Association of GAB2 with mutant SHP2 can also activate the PI3K/AKT/mechanistic target of Rapamycin (mTOR) pathway and inhibition of mTOR by rapamycin ameliorates myeloid cell expansion [41 & ]. Similar results have been shown with inactivation of the PI3K catalytic unit p110d or the regulatory unit coded by Pik3r1 in oncogenic Ptpn11 dependent model of JMML [42, 43] . In these studies, hypersensitivity to GM-CSF is lost in the absence of activation of the PI3K/AKT pathway. Consistent with these observations, a combination of SHP2 inhibitor IIB08 and PI3K inhibitor, LY294002 shows synergism in inhibiting cell proliferation and prolonging survival in receptor tyrosine kinase driven lung carcinoma and MPN models [30, 44] . Similar benefits of combined targeting have been observed in vitro with SHP2 inhibitor, IIB08 and SYK inhibitor R406 through their effects on STAT5 pathway in FLT3-ITD AML cells [45] . With the availability of newer more specific, potent, and well-tolerated SHP2 inhibitor such as SHP009, it should be possible to further explore the combinations that give best effect with least toxicity and off-target effects in hematological malignancies.
CONCLUSION
In conclusion, SHP2 is a crucial node for integration of signals from different cell surface receptors with all the major cellular signaling pathways within the cells. Therefore, while aberrant activation of SHP2 triggers activation of signaling pathways leading to the development of hematological malignancies; it also provides a vulnerable therapeutic target. However, given its ubiquitous expression and functional role in different tissues and organs further studies are needed before SHP2 targeted therapeutics enter the clinic.
